接受伊马替尼治疗的慢性髓性白血病患者的早期和迟发性皮肤不良事件。
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
作者信息
Breccia M, Carmosino I, Russo E, Morano S G, Latagliata R, Alimena G
机构信息
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.
出版信息
Eur J Haematol. 2005 Feb;74(2):121-3. doi: 10.1111/j.1600-0609.2004.00351.x.
Imatinib related non-haematological side-effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well-recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.
据报道，不到10%的慢性髓性白血病患者会出现伊马替尼相关的非血液学副作用，包括水肿、体重增加、恶心、呕吐和肌肉痉挛。皮肤反应是公认的事件，大多发生在接受600毫克/天及以上剂量治疗的患者中，无论疾病处于稳定期还是进展期。我们报告了我们在伊马替尼治疗的慢性髓性白血病患者中有关皮肤毒性的经验，这些患者表现出从皮疹到皮肤癌的一系列皮肤反应。
Zotero 插件